GLGaofeng Li

Gaofeng Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gaofeng Li has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Heng Li

    No. 2 Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China

    6 shared publications
  • Shuting Wang

    Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China

    4 shared publications
  • Benchao Chen

    No. 2 Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China

    3 shared publications
  • Anhao Wu

    Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China

    2 shared publications
  • Chao Liu

    Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China

    2 shared publications
  • Chunlei Ge

    Department of Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan 650118, P.R. China

    2 shared publications

Latest Publications

  • Open Access

    Identification of key genes as diagnostic biomarkers for lung adenocarcinoma using bioinformatics and machine learning

    by Zhiqing Liu, Chao Luo, Hanting Zhao, Lanjun Li, Xiao Ma, Jiacheng Wang, Shaobin Qiu, Tianshun Wang, Mingjie Li, Guoliang Li, et al.

    Background Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer; however, stable and reliable molecular diagnostic markers remain elusive. This study aimed to identify key genes with diagnostic utility and clinical relevance using bioinformatics and machine learning approaches. Methods Transcriptomic data from GEO datasets (GSE10072, GSE116959, GSE32863) were integrated with batch-effect correction. Differentially expressed genes (DEGs) were identified and analyzed by weighted gene co-expression network analysis (WGCNA); their overlap defined candidate genes for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. Summary data–based Mendelian randomization (SMR) using FinnGen lung adenocarcinoma data highlighted eight overlapping genes. The integrated GEO cohort was used for training, with GSE43458 and GSE75037 for external validation, to build machine-learning models and derive a five-gene diagnostic signature. Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) assessed immune infiltration and gene–immune associations, and prognostic/clinical relevance was validated in The Cancer Genome Atlas (TCGA-LUAD). Results Five key genes with excellent diagnostic performance (AUC > 0.8 in both the training and validation cohorts) were identified. These genes were closely associated with immune cell infiltration and immune-related features, and several showed significant correlations with overall survival and clinicopathological characteristics. Colocalization analysis indicated that ACVRL1 had a PP.H4 of 0.53 and a PP.H4/(PP.H3 + PP.H4) ratio of 0.97, suggesting a potential causal association between ACVRL1 and lung adenocarcinoma risk, with an inverse correlation. Conclusion By integrating multi-cohort transcriptomic data, SMR analysis, and machine learning approaches, this study identified five key genes with diagnostic potential for lung adenocarcinoma. Their immunological characteristics and clinical relevance were systematically evaluated. Colocalization analysis further suggested that ACVRL1 may be inversely and potentially causally associated with lung adenocarcinoma risk, providing new insights into lung adenocarcinoma pathogenesis and facilitating the identification of candidate molecular biomarkers.

  • Top Cited Papers
    Open Access

    Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC

    by Tetsuya Mitsudomi, John V. Heymach, Martin Reck, Janis M. Taube, Shugeng Gao, Yoshitsugu Horio, Jian You, Gaofeng Li, Dinh Van Luong, Somcharoen Saeteng, et al.


  • Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report

    by Xudong Xiang, Heng Li, Bao Lei, Benchao Chen, Gaofeng Li

    Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with limited treatment options, especially for extensive-stage (ES) patients. We present a case of a 70-year-old male with ES-SCLC... Plain language summary Small-cell lung cancer (SCLC) is a severe type of lung cancer that often does not have many treatment options, especially in its advanced stages. This article discusses the e...

  • Open Access

    The Risk of Cervical Cancer in Women Among Han, Bai, Dai and Hani Ethnic Minorities in Yunnan Province of China

    by Min Zhao, Ming-Zhu Gao, Rong-Yan Gu, Lei Luo, Song-Rui Ding, Liang He, Yue Jia, Hong-Ping Zhang, Hong-Ying Yang, Gao-Feng Li

    Background: Research on the risk factors for cervical cancer in Yunnan Province’s four characteristic ethnic groups (Han, Bai, Dai, and Hani) is lacking. Objective: To study the risk factors of cervical cancer in four ethnic women in Yunnan Province, and to provide evidence for its prevention. Methods: The cervical cancer patients of Han, Bai, Dai and Hani ethnic groups in Yunnan Province who were first diagnosed in the Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center) from January 2011 to December 2020 were selected as the research objects. The 1:1 matched case-control study method was used, and single factor and conditional logistic regression were used for statistical analysis. Results: HPV types 16, 18 and 58 are mostly related with cervical cancer, the younger the age of the last pregnancy, the more times of pregnancy, childbirth and abortion, especially the younger the first marriage age of Bai and Dai, are the risk factors of cervical cancer; the infection of genital tract bacteria, mycoplasma and chlamydia is closely related to the incidence of cervical cancer in four ethnicities. Multifactorial analysis showed that demographic characteristics and environment/behavior were not included in the influencing factors of cervical cancer; among Han, Bai, Dai and Hani ethnic minorities, contraception (OR=0.29, OR=0.03, OR=0.09, OR=0.16, P< 0.05) was positive factor, HPV infection (OR=64.77, OR=128.71, OR=71.89, OR=40.07, P< 0.01) was a causative factor of cervical cancer. Conclusion: Risk of high parity with cervical cancer could be due to a complex interplay of factors, it is very important to formulate prevention strategies and measures in line with the cervical cancer of Han, Bai, Dai and Hani ethnic groups women in Yunnan Province.


  • Open Access

    Mouse mesenchymal stem cell-derived exosomal miR-466f-3p reverses EMT process through inhibiting AKT/GSK3β pathway via c-MET in radiation-induced lung injury

    by Yi Li, Zhufu Shen, Xiao Jiang, Yuanyuan Wang, Zuozhang Yang, Yuchi Mao, Zhixian Wu, Gaofeng Li, Hong Chen

    Background: Radiation-induced lung fibrosis (RILF) is a common complication of thoracic radiotherapy. Alveolar epithelial cells play a crucial role in lung fibrosis via epithelial-mesenchymal transition (EMT). Exosomes derived from mesenchymal stem cells own the beneficial properties to repair and regeneration of damaged tissues, however the underlying mechanisms remain poorly understood. Methods: Mouse mesenchymal stem cells-derived exosomes (mMSCs-Exo) were isolated by differential centrifugation, and their protective effects were assessed in vivo and in vitro, respectively. EMT-associated proteins were measured via western blot assay and/or immunofluorescence staining. The miRNA expression was measured by microarray assay and qPCR. Furthermore, bioinformatics prediction with KEGG analysis, luciferase assay, and rescue experiments were performed to explore the molecular mechanism underlying miR-466f-3p. Results: mMSCs-Exos were efficiently isolated ranging from 90-150 nm with high expression of exosomal markers (CD63, TSG101, and CD9). mMSCs-Exos administration efficiently relieved radiation-induced lung injury with less collagen deposition and lower levels of IL-1β and IL-6. Meanwhile, in vitro results showed mMSCs-Exos treatment obviously reversed EMT process induced by radiation. Among enriched miRNA cargo in exosomes, miR-466f-3p was primarily responsible for the protective effects via inhibition of AKT/GSK3β pathway. Our mechanistic study further demonstrated that c-MET was the direct target of miR-466f-3p, whose restoration partially abrogated mMSCs-Exo-mediated inhibition in both EMT process and AKT/GSK3β signaling activity induced by radiation. Conclusions: Our findings indicated that exosomal miR-466f-3p derived from mMSCs may possess anti-fibrotic properties and prevent radiation-induced EMT through inhibition of AKT/GSK3β via c-MET, providing a promising therapeutic modality for radiation-induced lung fibrosis.


  • Open Access

    The Yunnan national medicine Maytenus compound inhibits the proliferation of hepatocellular carcinoma (HCC) by suppressing the activation of the EGFR-PI3K-AKT signaling pathway

    by Wen-Tao Zhao, Liu-Xin Han, Lin Liu, Bao-Zhen Zeng, Yi Zhang, Liu-Fang Zhao, Hong-Yan Hu, Jia-Wei Xia, Yi-Ze Li, Xu-Dong Xiang, et al.

    Objective: To investigate the effects of Maytenus compound on the proliferation of hepatocellular carcinoma (HCC) cells in vitro and in vivo and to explore the underlying mechanism.


  • Open Access

    Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis

    by Benchao Chen, Heng Li, Chao Liu, Xudong Xiang, Shuting Wang, Anhao Wu, Yan Shen, Gaofeng Li

    Background: Many previous studies have revealed that tumour-infiltrating lymphocytes (TILs) are significantly associated with prognosis in various tumours. However, this finding remains controversial in non-small cell lung cancer (NSCLC). We performed this meta-analysis systematically to evaluate the prognostic value of TILs in NSCLC. Methods: The references were collected by searching the PubMed, EMBASE and Web of Science databases. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were summarized using random or fixed effects models to evaluate the association between TILs and NSCLC survival outcomes. Results: A total of 45 interrelated studies were eligible that included 11,448 patients. Pooled analysis showed that a high density of TILs indicated a better overall survival (HR = 0.80, 0.70–0.89) and progression-free survival (HR = 0.73, 0.61–0.85) for patients with NSCLC; a high density of CD3+ TILs in the tumour nest indicated a better overall survival (HR = 0.84, 0.69–0.99) and disease-specific survival (HR = 0.57, 0.34–0.80); a high density of CD4+ TILs in the tumor nest indicated a favourable overall survival (HR = 0.86, 0.76–0.96); a high density of CD8+ TILs indicated a favourable overall survival (HR = 0.995, 0.99–1.0), progression-free survival (HR = 0.52, 0.34–0.71), disease-free survival (HR = 0.64, 0.43–0.85), relapse/recurrence-free survival (HR = 0.42, 0.18–0.67) and disease-specific survival (HR = 0.56, 0.35–0.78); and a high density of CD20+ TILs in the tumour nest indicated a favourable overall survival (HR = 0.65, 0.36–0.94). However, a high density of Foxp3+ TILs in the tumour stroma indicated a worse relapse/recurrence-free survival (HR = 1.90, 1.05–2.76) in NSCLC. Conclusions: Our meta-analysis confirmed that high densities of TILs, CD3+TILs, CD4+TILs, CD8+TILs and CD20+TILs in the tumour nest are favourable prognostic biomarkers for patients with NSCLC, and Foxp3+TILs in the tumour stroma are a poor prognostic biomarker.


  • Open Access

    Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis

    by Benchao Chen, Heng Li, Chao Liu, Shuting Wang, Feiyue Zhang, Li Zhang, Mingjie Li, Gaofeng Li

    Background: Current researches have revealed that delta-like protein 3 (DLL3) may be related with prognosis in patients with small cell lung cancer (SCLC). However, this finding remains controversial in small cell lung cancer. This meta-analysis was systematically performed to evaluate the prognostic value of DLL3 in SCLC. Methods: The PubMed, EMBASE and Web of Science databases were retrieved to collect the eligible references. Through Stata 15.0 software, we pooled hazard ratios (HR) with 95% confidence intervals (CI) by using random or fixed-effects models to evaluate the association between DLL3 and SCLC survival results. Results: A total of 6 inter-related studies including 645 patients were qualified. After we removed 1 study, the remaining 5 studies including 601 patients were pooled to testify that high expression of DLL3 was an inferior prognostic for patients with SCLC in Asian populations (HR = 1.37, 95% CI = 1.05, 1.69; I2 = 0.0%, p = 0.000). The pooled results showed that DLL3 might be higher expression in advanced metastasis SCLC in Asian populations (RR = 0.84, 95% CI = 0.71, 0.99; I2 = 44.7%, p = 0.039). But the expression of DLL3 was not correlated with sex (RR = 1.33, 95% CI = 0.98, 1.80; I2 = 0.0%, p = 0.064), smoking history (RR = 1.01, 95% CI = 0.58, 1.75; I2 = 72.1%, p = 0.967) and tumour stage (RR = 0.68, 95% CI = 0.44, 1.05; I2 = 66.6%, p = 0.081). Conclusions: Our meta-analysis confirms that in Asian populations, high expression of DLL3 was a potential poor prognostic biomarker for SCLC and DLL3 highly expressed in advanced stage SCLC in Asian populations.


    • 19 August 2020
      • Vol. 23  (10) , 916-920
    Open Access

    CAR-T免疫疗法与非小细胞肺癌:瓶颈与曙光

    by Li Zhang, Heng Li, Feiyue Zhang, Shuting Wang, Gaofeng Li

    伴随人们对威胁人类健康的非小细胞肺癌(non-small cell lung cancer, NSCLC)更深入的病理生理和发病机制的全新理解,NSCLC治疗已进入一个新时代。从传统以手术、放化疗为基础的治疗过渡到以个体化精准化的靶向治疗和安全性及效能更高的免疫治疗。免疫检查点抑制剂疗法已经被批准为晚期NSCLC一线或者二线的治疗方案,并且取得非同凡响的临床效果。然而,其他类型的免疫治疗在NSCLC中鲜有探索。嵌合抗原受体修饰T细胞(chimeric antigen receptor modified T cells, CAR-T cells)在治疗几种血液系统恶性肿瘤方面表现不俗。然而,其在治疗包括NSCLC在内的实体瘤患者方面却不甚理想。本综述旨在系统阐释CAR-T在NSCLC治疗中的最新进展,主要包括:CAR分子靶标选择、CAR-T功能增强及相关毒性的管理以及CAR-T治疗NSCLC的困境及展望,旨在为NSCLC的免疫治疗开拓新的视角和独特的思路,为肿瘤免疫治疗大厦添砖加瓦。


  • Open Access

    Increased expression of the RNA‑binding motif protein 47 predicts poor prognosis in non‑small‑cell lung cancer

    by Ruilei Li, Heng Li, Chunlei Ge, Qiaofen Fu, Zhen Li, Yarong Jin, Qinghua Tan, Zhitao Zhu, Zhiwei Zhang, Suwei Dong, et al.

    Lung cancer is the leading cause of cancer‑associated mortality worldwide. In China, in particular, lung cancer mortality has markedly increased and is likely to continue to rise. RNA‑binding proteins are pivotal to the development and progression of a variety of cancer types, including non‑small cell lung cancer (NSCLC). RNA‑binding motif protein 47 (RBM47) has been found to act as a tumor suppressor in breast cancer and NSCLC. However, to the best of our knowledge, RBM47 expression in NSCLC tissues has yet to be investigated. Analysis via the online database, Gene Expression Omnibus, revealed that RBM47 was upregulated in NSCLC and associated with pathological type, suggesting that RBM47 may play different roles in lung adenocarcinoma and lung squamous cell carcinoma. In the present study, the expression of RBM47 was examined by immunohistochemistry in 175 pairs of tumor and adjacent non‑cancerous tissues resected from patients with NSCLC. The results indicated that the expression of RBM47 was significantly increased in NSCLC samples compared with that in the matched non‑cancerous samples. Furthermore, RBM47 expression was higher in Xuanwei compared with that in non‑Xuanwei NSCLC, suggesting that RBM47 is a more sensitive biomarker in Xuanwei NSCLC, and that it may serve as a candidate therapeutic target. In addition, RBM47 expression was associated with the pathological type, however not with the age, sex, lymph node metastasis, pT stage or pathological Tumor‑Node‑Metastasis stage of the patients. The increased expression level of RBM47 may indicate a worse overall survival rate for patients with NSCLC. In addition, multivariate survival analysis showed that the Xuanwei area is associated with poor prognosis for patients with NSCLC. In conclusion, the present study revealed that the upregulation of RBM47 accelerated the malignant progression of NSCLC, indicating that RBM47 may be a potential biomarker for NSCLC progression and a therapeutic target for NSCLC.